Agennix AG (AGX)’s experimental treatment for non-small cell lung cancer failed to meet targets in a late-stage trial, casting doubt on the German biotechnology company’s future.
Talactoferrin, a replica of the human protein lactoferrin, didn’t meet its primary endpoint of improving overall survival rate, Agennix said today in a statement.
“We are extremely disappointed and surprised with today’s results, especially considering the earlier promising results we had seen in two randomized Phase II trials with talactoferrin alfa in non-small cell lung cancer,” said Rajesh Malik, chief medical officer. “We plan to thoroughly analyze the data to better understand these results.”
Tests of the drug involved 720 patients worldwide whose cancer hadn’t responded to two previous therapies. The primary target of the trial was overall survival and the secondary goal was the drug’s effectiveness in delaying or halting the spread of the disease.
To contact the reporter on this story: Allison Connolly in Frankfurt at firstname.lastname@example.org
To contact the editor responsible for this story: Phil Serafino at email@example.com